Patent SG-11201809173T-A (SG)
Title: Substituted bicyclic heterocyclic compounds
Inventor: GUNAGA PRASHANTHA
IPC: C07D471/04
Filed: 2017-04-19
Abstract: OrB) Riap W o \N W O 17 / 18 466 2 Al Formula (I) R 3 R4 X R2 R 1 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 October 2017 (26.10.2017) WIPO I PCT 0111111010 0111 Holm o Kill Imo mil (10) International Publication Number WO 2017/184662 Al (51) International Patent Classification: CO7D 471/04 (2006.01) A61K 31/519 (2006.01) CO7D 271/04 (2006.01) A61P 9/00 (2006.01) A61K 31/4725 (2006.01) (21) International Application Number: PCT/US2017/028231 (22) International Filing Date: 19 April 2017 (19.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/325,255 20 April 2016 (20.04.2016) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). (72) Inventors: GUNAGA, Prashantha; c/o Syngene Interna- tional Limited, Biocon Special Economic Zone, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase Jigani Link Road Bommasandra Bangalore, Karnata- ka 560 099 (IN). RICHTER, Jeremy; c/o Bristol-Myers Squibb Company, 350 Carter Road, Hopewell, New Jersey 08540 (US). YADAV, Navnath Dnyanoba; c/o Syngene International Limited, Biocon Special Economic Zone, Bio- con Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase Jigani Link Road Bommasandra Bangalore, Karnata- ka 560 099 (IN). PANDA, Manoranjan; c/o Syngene In- ternational Limited, Biocon Special Economic Zone, Bio- con Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase Jigani Link Road Bommasandra Bangalore, Karnata- ka 560 099 (IN). GODESI, Sreenivasulu; c/o Syngene In- ternational Limited, Biocon Special Economic Zone, Bio- con Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase Jigani Link Road Bommasandra Bangalore, Karnata- ka 560 099 (IN). (74) Agent: VANATTEN, Mary K. et al.; Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4. 1 7(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4 . 17 (iii)) of inventorship (Rule 4.1 7(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) = (54) Title: SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS (57) : Disclosed are compounds of Formula (I), or a salt thereof, wherein: X is CR4 or N; Y is CR4 or N, provided that Y is N only if X is N; R] is Formulae (A) or (B); each W is independently NRib or 0; Z is a bond or CHRid; and Ri, R2, R3, R4, Li, Ri a , Rib, Ri , and n are defined herein. Also disclosed are methods of using such c compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.